At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
Nivolumab +1 moredrug
Likely dose
Nivolumab 480mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Nivolumab in Combination With Talazoparib in Patients With Unresectable or Metastatic Melanoma and Mutations in BRCA or BRCA-ness Genes
In Brief
A Phase 2 clinical trial evaluating Nivolumab and Talazoparib for Metastatic or Unresectable Melanoma. Completed, enrolled 8 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate how effective the study drugs, nivolumab (also known as Opdivo®) and talazoparib (also known as Talzenna®) are when given as a combination treatment for unresectable or metastatic melanoma. The study team wants to know the effectiveness of these drugs together in treating cancer than if each study drug was given by itself.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic or Unresectable Melanoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedDec 2019
Enrollment StartJun 2020
Primary CompletionOct 2023
TodayJul 2026
First PostedDec 5, 2019
Enrollment StartJun 5, 2020
Primary CompletionOct 13, 2023
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 6.6 years ago
Interventions
Nivolumabdrug
480mg intravenously every 4 weeks (28 days)
Talazoparibdrug
1mg orally daily